{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:33:59Z","timestamp":1788932039776,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s11095-025-03918-z","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:56Z","timestamp":1760125916000},"page":"1717-1732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Preclinical Evaluation of AAV8-R338L Gene Therapy for Hemophilia: Efficacy, Pharmacokinetics, Distribution, Excretion and Toxicity in Mouse Models and Non-human Primates"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3622-6412","authenticated-orcid":false,"given":"Dehu","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxia","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3918_CR1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.7326\/M19-1208","volume":"171","author":"A Iorio","year":"2019","unstructured":"Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171:540\u20136.","journal-title":"Ann Intern Med"},{"key":"3918_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-47.","journal-title":"Haemophilia"},{"issue":"1","key":"3918_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1182\/hematology.2021000254","volume":"2021","author":"LA George","year":"2021","unstructured":"George LA. Hemophilia gene therapy: ushering in a new treatment paradigm? Hematology Am Soc Hematol Educ Program. 2021;2021(1):226\u201333.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"3918_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1056\/NEJMoa2211644","volume":"388","author":"SW Pipe","year":"2023","unstructured":"Pipe SW, Leebeek FWG, Recht M, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023;388(8):706\u201318.","journal-title":"N Engl J Med"},{"issue":"23","key":"3918_CR5","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"S Tiefenbacher","year":"2017","unstructured":"Tiefenbacher S, Arruda VR, van der Loo JCM, et al. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med. 2017;377(23):2215\u201327.","journal-title":"N Engl J Med"},{"issue":"9","key":"3918_CR6","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","volume":"131","author":"W Miesbach","year":"2018","unstructured":"Miesbach W, Meijer K, Coppens M, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131(9):1022\u201331.","journal-title":"Blood"},{"key":"3918_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","volume":"21","author":"A Srivastava","year":"2016","unstructured":"Srivastava A. In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol. 2016;21:75\u201380. https:\/\/doi.org\/10.1016\/j.coviro.2016.08.003.","journal-title":"Curr Opin Virol"},{"key":"3918_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2019.02.005","author":"KI Berns","year":"2019","unstructured":"Berns KI, Srivastava A. Next generation of adeno-associated virus vectors for gene therapy for human liver diseases. Gastroenterol Clin North Am. 2019. https:\/\/doi.org\/10.1016\/j.gtc.2019.02.005.","journal-title":"Gastroenterol Clin North Am"},{"key":"3918_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcma.2013.07.007","author":"C-H Chiang","year":"2013","unstructured":"Chiang C-H, Chien Y, Hsieh J-H, et al. Induced pluripotent stem cells and hepatic differentiation. J Chin Med Assoc. 2013. https:\/\/doi.org\/10.1016\/j.jcma.2013.07.007.","journal-title":"J Chin Med Assoc"},{"issue":"8","key":"3918_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.omtm.2018.01.003","volume":"31","author":"B Silva Lima","year":"2018","unstructured":"Silva Lima B, Videira MA. Toxicology and biodistribution: the clinical value of animal biodistribution studies. Mol Ther Methods Clin Dev. 2018;31(8):183\u201397. https:\/\/doi.org\/10.1016\/j.omtm.2018.01.003.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"3918_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1208\/s12248-021-00678-7","volume":"24","author":"N Chen","year":"2022","unstructured":"Chen N, Sun K, Chemuturi NV, et al. The perspective of DMPK on recombinant adeno-associated virus-based gene therapy: past learning, current support, and future contribution. AAPS J. 2022;24(1):31. https:\/\/doi.org\/10.1208\/s12248-021-00678-7.","journal-title":"AAPS J"},{"key":"3918_CR12","unstructured":"FDA.Approval-History--Letters--Reviews-and-Related-Documents-HEMGENIX[EB\/OL]. (2022\u201311). https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/hemgenix.\u00a0Accessed 28 May 2025."},{"issue":"2","key":"3918_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/humc.2017.253","volume":"29","author":"W Miesbach","year":"2018","unstructured":"Miesbach W, Sawyer EK. Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective. Hum Gene Ther Clin Dev. 2018;29(2):80\u20139.","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"Suppl 2","key":"3918_CR14","first-page":"S79","volume":"62","author":"K Sun","year":"2022","unstructured":"Sun K, Liao MZ. Clinical Pharmacology Considerations on Recombinant Adeno-Associated Virus-Based Gene Therapy. J Clin Pharmacol. 2022;62(Suppl 2):S79\u201394.","journal-title":"J Clin Pharmacol"},{"issue":"1\u20132","key":"3918_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41434-023-00417-x","volume":"31","author":"M Singh","year":"2024","unstructured":"Singh M, Brooks A, Toofan P, McLuckie K. Selection of appropriate non-clinical animal models to ensure translatability of novel AAV-gene therapies to the clinic. Gene Ther. 2024;31(1\u20132):56\u201363.","journal-title":"Gene Ther"},{"issue":"9\u201310","key":"3918_CR16","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1089\/hum.2022.29210.amg","volume":"33","author":"AM Gruntman","year":"2022","unstructured":"Gruntman AM, Flotte TR. Gene therapy and the use of animal models: why mice alone are not sufficient. Hum Gene Ther. 2022;33(9\u201310):477\u20138.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"3918_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20(3):173\u20134.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3918_CR18","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-022-33745-4","volume":"13","author":"TJ Gonzalez","year":"2022","unstructured":"Gonzalez TJ, Simon KE, Blondel LO. Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat Commun. 2022;13(1):5947.","journal-title":"Nat Commun"},{"issue":"25","key":"3918_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","volume":"26","author":"JR Mendell","year":"2022","unstructured":"Mendell JR, Connolly AM, Lehman KJ. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol Ther Methods Clin Dev. 2022;26(25):74\u201383.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3918_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"3918_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/978-1-61779-370-7_11","volume":"807","author":"AT Martino","year":"2011","unstructured":"Martino AT, Herzog RW, Anegon I, et al. Measuring immune responses to recombinant AAV gene transfer. Methods Mol Biol. 2011;807:259\u201372.","journal-title":"Methods Mol Biol"},{"key":"3918_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymeth.2020.12.001","volume":"194","author":"W Wu","year":"2021","unstructured":"Wu W, Yang Y, Yao F, Dong L, et al. AAV-mediated in vivo genome editing in vascular endothelial cells. Methods. 2021;194:12\u20137.","journal-title":"Methods"},{"key":"3918_CR23","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1089\/hum.2011.031","volume":"22","author":"L Wang","year":"2011","unstructured":"Wang L, Calcedo R, Bell P. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther. 2011;22:1389\u2013401.","journal-title":"Hum Gene Ther"},{"key":"3918_CR24","doi-asserted-by":"publisher","first-page":"107453","DOI":"10.1016\/j.pharmthera.2019.107453","volume":"207","author":"NF Nidetz","year":"2020","unstructured":"Nidetz NF, McGee MC, Tse LV, et al. Adeno-associated viral vector-mediated immune responses: understanding barriers to gene delivery. Pharmacol Ther. 2020;207:107453.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"3918_CR25","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876\u201385.","journal-title":"Mol Ther"},{"key":"3918_CR26","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","volume":"107","author":"AC Nathwani","year":"2006","unstructured":"Nathwani AC, Gray JT, Ng CY, et al. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood. 2006;107:2653\u201361.","journal-title":"Blood"},{"key":"3918_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1089\/hum.2020.29117.trf","volume":"31","author":"TR Flotte","year":"2020","unstructured":"Flotte TR. Revisiting the \u201cNew\u201d Inflammatory Toxicities of Adeno-Associated Virus Vectors. Hum Gene Ther. 2020;31:398\u20139.","journal-title":"Hum Gene Ther"},{"key":"3918_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/psp4.12597","volume":"10","author":"A Belov","year":"2021","unstructured":"Belov A, Schultz K, Forshee R. Opportunities and challenges for applying model-informed drug development approaches to gene therapies. CPT Pharmacometrics Syst Pharmacol. 2021;10:286\u201390.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3918_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ces.2023.119073","author":"E Jamili","year":"2023","unstructured":"Jamili E, Nathwani AC, Dua V. Mathematical modelling of gene delivery in patients with haemophilia B. Chem Eng Sci. 2023. https:\/\/doi.org\/10.1016\/j.ces.2023.119073.","journal-title":"Chem Eng Sci"},{"key":"3918_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.addr.2021.01.017","volume":"170","author":"EA Chowdhury","year":"2021","unstructured":"Chowdhury EA, Meno-Tetang G, Chang HY. Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic\/pharmacodynamic (PK\/PD) models. Adv Drug Deliv Rev. 2021;170:214\u201337.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"3918_CR31","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther. 2011;19(5):876\u201385.","journal-title":"Mol Ther"},{"issue":"15","key":"3918_CR32","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.omtm.2019.09.005","volume":"26","author":"EA Spronck","year":"2019","unstructured":"Spronck EA, Liu YP, Lubelski J. Enhanced Factor IX Activity following Administration of AAV5-R338L \u201cPadua\u201d Factor IX versus AAV5 WT Human Factor IX in NHPs. Mol Ther Methods Clin Dev. 2019;26(15):221\u201331.","journal-title":"Mol Ther Methods Clin Dev"}],"updated-by":[{"DOI":"10.1007\/s11095-026-04125-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000}}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03918-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03918-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T18:47:35Z","timestamp":1779994055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03918-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3918"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03918-z","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to add Dr. Xijing Chen as Co-Corresponding Author.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11095-026-04125-0","URL":"https:\/\/doi.org\/10.1007\/s11095-026-04125-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}